EGF is involved in endothelial dysfunction, neointimal hyperplasia, cardiac hypertrophy and remodeling [88] and, as shown by us, reduction in circulating levels of EGF could be involved in the ticagrelor-mediated improvement of endothelial function in stable CAD/COPD patients [2]. The gene discussed is EGF; the disease is coronary artery disorder.